Loading…
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-178M | $-174M | $-157M | -96.8% | - | 39.8% |
| 2024 | $0M | $-122M | $-125M | $-101M | -90.9% | - | 29.9% |
| 2023 | $0M | $-93M | $-96M | $-96M | -75.9% | -100.0% | 11.7% |
| 2022 | $8M | $-97M | $-86M | $-101M | -40.6% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 8.09 | 0 | 0 | 0 |
| Operating Revenue | - | 8.09 | 0 | 0 | 0 |
| Operating Expense | - | 107.37 | 104.32 | 129.73 | 179.21 |
| Research And Development | - | 78.42 | 76.56 | 96.43 | 140.32 |
| Selling General And Administration | - | 28.95 | 27.75 | 33.30 | 38.88 |
| Total Expenses | - | 107.37 | 104.32 | 129.73 | 179.21 |
| Operating Income | - | -99.27 | -104.32 | -129.73 | -179.21 |
| Total Operating Income As Reported | - | -106.45 | -104.25 | -129.73 | -179.21 |
| EBITDA | - | -96.87 | -92.99 | -121.90 | -177.57 |
| Normalized EBITDA | - | -107.92 | -93.06 | -117.15 | -171.52 |
| EBIT | - | -99.27 | -95.58 | -124.36 | -179.21 |
| Interest Income | - | 2.62 | 7.58 | 9.47 | 10.11 |
| Interest Expense | - | - | 0.44 | 0.34 | - |
| Net Interest Income | - | 2.62 | 7.14 | 9.13 | 10.11 |
| Other Non Operating Income Expenses | - | -0.38 | 1.10 | 0.65 | 0.82 |
| Other Income Expense | - | 10.68 | 1.16 | -4.10 | -5.23 |
| Interest Income Non Operating | - | 2.62 | 7.58 | 9.47 | 10.11 |
| Interest Expense Non Operating | - | - | 0.44 | 0.34 | - |
| Net Non Operating Interest Income Expense | - | 2.62 | 7.14 | 9.13 | 10.11 |
| Pretax Income | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income From Continuing And Discontinued Operation | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income From Continuing Operation Net Minority Interest | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income Common Stockholders | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Net Income Including Noncontrolling Interests | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Normalized Income | - | -97.04 | -96.08 | -119.95 | -168.28 |
| Diluted NI Availto Com Stockholders | - | -85.98 | -96.02 | -124.70 | -174.32 |
| Basic Average Shares | 7.12 | 8.51 | 19.88 | 40.82 | - |
| Diluted Average Shares | 7.12 | 8.51 | 19.88 | 40.82 | - |
| Reconciled Depreciation | - | 2.41 | 2.58 | 2.46 | 1.64 |
| Total Unusual Items | - | 11.06 | 0.06 | -4.75 | -6.05 |
| Total Unusual Items Excluding Goodwill | - | 11.06 | 0.06 | -4.75 | -6.05 |
| Special Income Charges | 0 | 11.06 | 0.06 | 0 | - |
| Restructuring And Mergern Acquisition | 0 | -11.06 | -0.06 | 0 | - |
| Gain On Sale Of Security | - | - | - | -4.75 | -6.05 |
| General And Administrative Expense | - | 28.95 | 27.75 | 33.30 | 38.88 |
| Other Gand A | - | 28.95 | 27.75 | 33.30 | 38.88 |
| Total Other Finance Cost | -0.06 | -2.62 | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Solid Biosciences Inc.this co. | SLDB | $713M | -4.09 | 3.96 | -96.8% | -3.80 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| HealthStream, Inc. | HSTM | $739M | 40.28 | 2.09 | 5.2% | 11.26 |
| Bright Minds Biosciences Inc. | DRUG | $731M | -59.77 |
| - |
| - |
| - |
| - |
| 8.91 |
| -14.9% |
| -46.77 |
| CBLL | CBLL | $711M | -13.32 | 4.58 | -34.4% | -13.81 |
| Enhabit, Inc. | EHAB | $707M | -153.68 | 1.32 | -0.9% | 20.09 |
| Allogene Therapeutics, Inc. | ALLO | $704M | -3.69 | 2.41 | -65.3% | -4.15 |
| Aura Biosciences, Inc. | AURA | $703M | -6.62 | 5.13 | -77.6% | -5.92 |
| Peer Median | - | -12.07 | 3.02 | -24.2% | -6.95 | |